Cannabinoids and the placenta: Receptors, signaling and outcomes
- PMID: 36965349
- DOI: 10.1016/j.placenta.2023.03.002
Cannabinoids and the placenta: Receptors, signaling and outcomes
Abstract
Cannabis use during pregnancy is increasing. The improvement of pregnancy-related symptoms including morning sickness and management of mood and stress are among the most reported reasons for its use. Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) are the most abundant cannabinoids found within the cannabis flower. The concentration of these components has drastically increased in the past 20 years. Additionally, many edibles contain only one cannabinoid and are marketed to achieve a specific goal, meaning there are an increasing number of pregnancies that are exposed to isolated cannabinoids. Both Δ9-THC and CBD cross the placenta and can impact the fetus directly, but the receptors through which cannabinoids act are also expressed throughout the placenta, suggesting that the effects of in-utero cannabinoid exposure may include indirect effects from the placenta. In-utero cannabis research focuses on short and long-term fetal health and development; however, these studies include little to no placenta analysis. Prenatal cannabinoid exposure is linked to small for gestational age and fetal growth-restricted babies. Compromised placental development is also associated with fetal growth restriction and the few studies (clinical and animal models) that included placental analysis, identify changes in placental vasculature and function in these cannabinoid-exposed pregnancies. In vitro studies further support cannabinoid impact on cell function in the different populations that comprise the placenta. In this article, we aim to summarize how phytocannabinoids can impact placental development and function. Specifically, the cannabinoids and their actions at the different receptors are described, with receptor localization throughout the human and murine placenta discussed. Findings from studies that included placental analysis and how cannabinoid signaling may modulate critical developmental processing including cell proliferation, angiogenesis and migration are described. Considering the current research, prenatal cannabinoid exposure may significantly impact placental development, and, as such, identifying windows of placental vulnerability for each cannabinoid will be critical to elucidate the etiology of fetal outcome studies.
Copyright © 2023 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of competing interest We have no conflicts of interest to disclose.
Similar articles
-
Suppression of STAT3 Signaling by Δ9-Tetrahydrocannabinol (THC) Induces Trophoblast Dysfunction.Cell Physiol Biochem. 2017;42(2):537-550. doi: 10.1159/000477603. Epub 2017 Jun 5. Cell Physiol Biochem. 2017. PMID: 28578322
-
Expression of the endocannabinoid system and response to cannabinoid components by the human fetal testis.BMC Med. 2023 Jul 11;21(1):219. doi: 10.1186/s12916-023-02916-5. BMC Med. 2023. PMID: 37430350 Free PMC article.
-
Effects of a combination of cannabidiol and delta-9-tetrahydrocannabinol on key biological functions of HTR-8/SVneo extravillous trophoblast cells.Toxicology. 2023 Aug 15;495:153614. doi: 10.1016/j.tox.2023.153614. Epub 2023 Aug 9. Toxicology. 2023. PMID: 37567336
-
Metabolic Consequences of Gestational Cannabinoid Exposure.Int J Mol Sci. 2021 Sep 2;22(17):9528. doi: 10.3390/ijms22179528. Int J Mol Sci. 2021. PMID: 34502436 Free PMC article. Review.
-
The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.Br J Pharmacol. 2008 Jan;153(2):199-215. doi: 10.1038/sj.bjp.0707442. Epub 2007 Sep 10. Br J Pharmacol. 2008. PMID: 17828291 Free PMC article. Review.
Cited by
-
Prenatal Cannabis Use and Maternal Pregnancy Outcomes.JAMA Intern Med. 2024 Jul 22:e243270. doi: 10.1001/jamainternmed.2024.3270. Online ahead of print. JAMA Intern Med. 2024. PMID: 39037795 Free PMC article.
-
The impact of recreational cannabinoid legalization on utilization in a pregnant population.Front Public Health. 2024 Feb 20;12:1278834. doi: 10.3389/fpubh.2024.1278834. eCollection 2024. Front Public Health. 2024. PMID: 38444440 Free PMC article.
-
Prenatal cannabinoid exposure: why expecting individuals should take a pregnancy pause from using cannabinoid products.Front Pediatr. 2023 Oct 11;11:1278227. doi: 10.3389/fped.2023.1278227. eCollection 2023. Front Pediatr. 2023. PMID: 37886232 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous